The gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence

American Journal of Surgical Pathology

Volumn 34, Issue 7, 2010, Pages 994-1001

  Cao, Dengfeng ^a   Kibel, Adam S ^a   Gao, Feng ^a   Tao, Yu ^a   Humphrey, Peter A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biochemical recurrence; Gleason score of tumor at the margin; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954217089     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181e103bf     Document Type: Article

References (39)

1. Babaian RJ, Troncoso P, Bhadkamkar VA, et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91:1414-1422.
2. Blute ML, Bostwick DG, Bergstralh EJ, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50:733-739.
3. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-578.
4. Cao D, Humphrey PA, Gao F, et al. The linear length of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. J Urol. Submitted, 2010.
5. Chuang AY, Nielsen ME, Hernandez DJ, et al. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol. 2007; 178:1306-1310.
6. Connolly SS, O'Toole GC, O'Malley KJ, et al. Positive apical surgical margins after radical retropubic prostatectomy, truth or artefact?. Scand J Urol Nephrol. 2004;38:26-31.
7. Eastham JA, Kuroiwa K, Ohori M, et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007;70:965-969 (Pubitemid 350192610)
8. Eble JN, Sauter G, Epstein Ji, et al. eds. Pathology and Genetics of Tumors of the Urinary Systems and Male Genital organs. Lyon: IARD Press; 2004;159-214.
9. Edge SB, Bryd DR, Compton CC, et al. eds. AJCC Cancer staging manual. Springer. 2009;457-468.
10. Emerson RE, Koch MO, Jones TD, et al. The influence of extent of surgical margin positivity on prostate specific antigen recurrence. J Clin Pathol. 2005;58:1028-1032.
11. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582-3593.
12. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286-292.
13. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29: 1228-1242.
14. Epstein JI, Humphrey PA, Cubilla AL. Tumors of the prostate gland, seminal vesicles, and penis. AFIP Fascicle. 2010. In press.
15. Gleason DF. Classification of prostatic carcinomas. Cancer Che-mother Rep. 1966;50:125-128.
16. Godoy G, Tareen BU, Lepor H. Is the apical soft tissue margin a better predictor of biochemical recurrence than the surgical specimen?. Urol Oncol. 2009. [Epub ahead of print]
17. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol. 1992;16:315-324.
18. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-565.
19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
20. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167: 528-534.
21. Kausik SJ, Blute ML, Sebo TJ, et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002;95:1215-1219.
22. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866-871.
23. Kordan Y, Salem S, Chang SS, et al. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009;182:2695-2701.
24. Kupelian P, Katcher J, Levin H, et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 1996;48:249-260.
25. Lennernas B, Edgren M, Haggman M, et al. Postoperative radiotherapy after prostatectomy-a review. Scand J Urol Nephrol. 2003;37:10-15.
26. Marks RA, Koch MO, Lopez-Beltran A, et al. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol. 2007;38:1207-1211.
27. Mian BM, Troncoso P, Okihara K, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002;167:1675-1680.
28. Nielsen ME, Trock BJ, Walsh PC. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw. 2010;8:228-237.
29. Obek C, Sadek S, Lai S, et al. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. 1999;54:682-688.
30. Ochiai A, Sotelo T, Troncoso P, et al. Natural history of biochemical progression after radical prostatectomy based on length of a positive margin. Urology. 2008;71:308-312.
31. Resnick MJ, Canter DJ, Guzzo TJ, et al. Defining pathological variables to predict biochemical failure in patients with positive surgical margins at radical prostatectomy: implications for adjuvant radiotherapy. BJU Int. 2009. [Epub ahead of print]
32. Shikanov S, Song J, Royce C, et al. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009;182:139-144.
33. Sofer M, Hamilton-Nelson KL, Civantos F, et al. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol. 2002;167: 2453-2456.
34. Srigley JR, Humphrey PA, Amin MB, et al. Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patiens with carcinoma of the prostate. Arch Pathol Lab Med. 2009;133:1568-1576.
35. Stephenson AJ, Wood DP, Kattan MW, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182:1357-1363.
36. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335.
37. Vis AN, Schroder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50:258-265.
38. Weldon VE, Tavel FR, Neuwirth H, et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol. 1995;153:1565-1569.
39. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-2930.